YOLFTbeta
Cellectis S.A.

Cellectis S.A.

0WA2 · LSE

1.05EUR-0.19 (-15.38%)

Price History

Full chart

Market Stats

Previous Close1.24
Open1.08
Day Range1.05 – 2.84
52-Week Range1.10 – 4.84
Volume0
Market Cap229.49M
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta2.77
50-Day Avg1.81
200-Day Avg2.02

About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Company Details

  • CEODr. Andre Choulika Ph.D.
  • Employees224
  • Headquarters8, rue de la Croix Jarry, Paris, France, 75013, UK
  • Websitehttps://www.cellectis.com

Leadership

  • Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director · b. 1965
  • Dr. David J. Sourdive Ph.D.Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director · b. 1967
  • Mr. Arthur StrilCFO & Chief Business Officer · b. 1989
  • Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat Ph.D.Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D.Chief Scientific Officer · b. 1963
  • Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors · b. 1982
  • Pascalyne WilsonDirector of Communications
  • Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer · b. 1970
  • Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance Officer · b. 1969

Financials

Income Statement

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue56.44M33.72M21.43M22.99M82.46M--
Growth (%)--40.27%-36.43%+7.27%+258.66%--
Cost of Revenue36.57M47.60M54.71M60.68M56.63M--
Gross Profit19.87M-13.88M-33.28M-37.69M25.83M--
Gross Margin35.20%-41.17%-155.27%-163.95%31.32%--
Operating Expense87.17M78.77M71.81M85.86M111.27M--
Operating Income-67.30M-92.65M-105.09M-123.55M-85.44M--
Operating Margin-119.24%-274.80%-490.35%-537.42%-103.62%--
Net Income-67.25M-99.37M-78.69M-102.09M-81.07M--
Net Income Margin-119.15%-294.73%-367.18%-444.07%-98.32%--
Interest Expense000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%--

Balance Sheet

Currency: EUR2015-12-312016-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets-331.43M500.84M467.47M469.47M--
Total Liabilities-58.64M91.54M152.35M193.90M--
Total Equity-272.80M409.30M315.12M275.57M--
Cash-69.07M53.32M69.89M76.56M--
Total Debt-30.00K1.02M46.54M104.60M--

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-32.71M-52.33M-68.14M-69.14M-80.26M-104.56M-87.44M--
Investing Cash Flow-53.14M1.78M35.62M-35.87M-54.34M7.28M-2.76M--
Financing Cash Flow485.00K41.27M236.49M-3.86M27.32M47.52M1.15M--
Capital Expenditure53.34M5.25M4.71M12.91M44.08M18.54M2.43M00

Earnings

Report DateMar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 13, 2024May 28, 2024Aug 6, 2024Nov 4, 2024Dec 31, 2024Mar 31, 2025Aug 4, 2025Nov 7, 2025Mar 19, 2026May 18, 2026Aug 6, 2026Nov 13, 2026
EPS Estimate-----------------------------------
EPS Actual-0.57-0.14-0.46-0.48-0.32-0.70-0.34-0.790.43-0.69-0.61-0.78-0.23-0.73-0.70-0.48-0.63-0.39-0.62-0.58-0.54-0.18-0.29-0.560.05-0.26-0.210.08-0.17-0.210.01-0.23-0.15-0.19-
Surprise-----------------------------------
Timing-----------------------After-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap229.49M
Enterprise Value11.88M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
Book Value0.4928
Revenue (TTM)63.82M
Gross Profit (TTM)63.82M
EBITDA-46.68M
Profit Margin-102.34%
Operating Margin-340.69%
Return on Equity-94.54%
Return on Assets-11.67%
Shares Outstanding0
Shares Float48.58M
Beta2.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%